These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 2091765)
21. [Characteristics, indications for and adverse effects of various preparations with immunologic properties]. Niedworok J Wiad Lek; 1988 Aug; 41(15):1039-47. PubMed ID: 3245193 [No Abstract] [Full Text] [Related]
22. [What is certain in the treatment with immunosuppressive agents?]. Malchow H Internist (Berl); 1971 Dec; 12(12):504-12. PubMed ID: 4944681 [No Abstract] [Full Text] [Related]
23. Immunomodulation by n-3 polyunsaturated fatty acids. Netea MG; Kullberg BJ; Blok WL; Van der Meer JW Immunol Today; 1999 Feb; 20(2):103. PubMed ID: 10098331 [No Abstract] [Full Text] [Related]
24. [Immunosuppression in the kidney transplant. Old drugs and new acquisitions]. Rodríguez Ferrero M; Valderrábano F Rev Clin Esp; 1997 Oct; 197(10):703-12. PubMed ID: 9424669 [No Abstract] [Full Text] [Related]
25. Toward a role for statins in immunomodulation. Mach F Mol Interv; 2002 Dec; 2(8):478-80. PubMed ID: 14993398 [TBL] [Abstract][Full Text] [Related]
26. Modern therapeutic strategies for autoimmune diseases. Tyndall A Curr Pharm Des; 2012; 18(29):4508-12. PubMed ID: 22612754 [TBL] [Abstract][Full Text] [Related]
27. Immunomodulation by interleukin-2 receptor targeted therapy. Gupta D; Naik S Natl Med J India; 1994; 7(2):67-70. PubMed ID: 8019399 [TBL] [Abstract][Full Text] [Related]
28. Clinical applications of cytokines for immunostimulation and immunosuppression. Lee B; Ciardelli TL Prog Drug Res; 1992; 39():167-96. PubMed ID: 1475362 [No Abstract] [Full Text] [Related]
29. Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease. Plettenberg H; Assmann T; Ruzicka T Arch Dermatol; 2003 May; 139(5):651-4. PubMed ID: 12756103 [No Abstract] [Full Text] [Related]
30. Ex vivo and in vivo characterization of biological response modifiers (BRMs). Masihi KN; Talmadge JE Dev Biol Stand; 1992; 77():143-5. PubMed ID: 1426655 [No Abstract] [Full Text] [Related]
31. Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis. Tumani H; Uttner I J Neurol; 2007 May; 254 Suppl 2():II69-72. PubMed ID: 17503133 [TBL] [Abstract][Full Text] [Related]
32. [Effect of drug preparations on IgE antibody production]. Ionov ID Farmakol Toksikol; 1986; 49(4):105-8. PubMed ID: 3530803 [No Abstract] [Full Text] [Related]
33. [Possibilities and current trends of biological immunosuppression in organ and tissue transplantation. I]. Păuşescu E Microbiol Parazitol Epidemiol (Bucur); 1973; 18(5):437-58. PubMed ID: 4588358 [No Abstract] [Full Text] [Related]
34. [Immunosuppression and immunopotentiation in the treatment of skin diseases]. Wereide K Tidsskr Nor Laegeforen; 1983 Apr; 103(10):841-4. PubMed ID: 6879520 [No Abstract] [Full Text] [Related]
35. Outlook for immune intervention in type I diabetes. Grob PJ Curr Probl Clin Biochem; 1983; 12():119-40. PubMed ID: 6360542 [No Abstract] [Full Text] [Related]
36. Immunopharmacology. Immunomodulation and immunotherapy. Hadden JW JAMA; 1987 Nov; 258(20):3005-10. PubMed ID: 3312684 [No Abstract] [Full Text] [Related]
37. [Current trends in the study of immunosuppressive agents]. Uteshev BS Farmakol Toksikol; 1981; 44(1):5-12. PubMed ID: 6455303 [TBL] [Abstract][Full Text] [Related]